ArticlePloS one2013
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Development of a novel anti-human glypican 5 monoclonal antibody (GBiochemistry and biophysics reports · 2025Article
- Genetic Contribution to Medium-Term Disease Activity in Multiple Sclerosis.Molecular neurobiology · 2025Article
- CXCL12 Gene Polymorphisms and Serum Levels: Associations with Multiple Sclerosis Prevalence and Clinical Parameters in Lithuania.International journal of molecular sciences · 2024Article
- Drosophila Evi5 is a critical regulator of intracellular iron transport via transferrin and ferritin interactions.Nature communications · 2024Article
- Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.Journal of comparative effectiveness research · 2023Article
- Genetic risk factors for ME/CFS identified using combinatorial analysis.Journal of translational medicine · 2022Article
- Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.PharmacoEconomics - open · 2022Article
- Clinicopathologic and molecular analysis of aCold Spring Harbor molecular case studies · 2022Article
- M-Phase Phosphoprotein 9 upregulation associates with poor prognosis and activates mTOR signaling in gastric cancer.The Kaohsiung journal of medical sciences · 2021Article
- Replication analysis of variants associated with multiple sclerosis risk.Scientific reports · 2020Article
- Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation.Cellular & molecular immunology · 2019Article
- Environmental and genetic risk factors for MS: an integrated review.Annals of clinical and translational neurology · 2019Review
- Genetic and Environmental Predictors of Adolescent PTSD Symptom Trajectories Following a Natural Disaster.Brain sciences · 2019Article
- The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis.Genes and immunity · 2019Article
- The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults.Multiple sclerosis and related disorders · 2018Article
- Genetic predictors of relapse rate in pediatric MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2016Article
- Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.Neurology. Genetics · 2016Article
- Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability.Neurogenetics · 2015Article
- The Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MS.Multiple sclerosis journal - experimental, translational and clinicalArticle
- A Powerful Global Test Statistic for Functional Statistical Inference.Proceedings of the ... AAAI Conference on Artificial Intelligence. AAAI Conference on Artificial IntelligenceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with early multiple sclerosis (MS) have stereotyped attack severity and recovery. We sought to determine if polymorphisms in MS susceptibility genes are associated with these attack features or with the risk of a second attack.
methods503 white subjects evaluated within a year of MS onset were included in the study. The severity of and recovery from the first two attacks were determined based on published definitions. Seventeen MS susceptibility genes were genotyped at the UCSF MS Genetics laboratory. Each polymorphism was evaluated in multivariate ordinal models, adjusted for the other polymorphisms, for its association with attack severity and recovery. We also assessed if these polymorphisms were associated with increased risk of a second attack.
resultsThe MPHOSPH9 polymorphism was associated with greater attack severity (odds ratios [OR] = 1.47, 95% CI [1.11, 1.94], p = 0.008), while the RGS1 and TNFRSF1A polymorphisms tended to be associated with reduced attack severity. The CD6 polymorphism tended to be associated with increased odds of worse attack recovery (OR = 1.25, 95% CI [0.93, 1.68], p = 0.13). In those who were HLA-DRB1-negative, the EVI5 polymorphism was associated with attacks of less severity; in HLA-DRB1 positive patients, EVI5 was associated with attacks of greater severity and worse recovery. The IL7R, TNFRSF1A, and GPC5 polymorphisms tended to be associated with having a second event within a year.
conclusionsSome MS susceptibility polymorphisms may be associated with attack severity, recovery, or frequency. Further characterization of these genes may lead to a better understanding of MS pathogenesis and to a more individualized treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.